Tharimmune Stock Annual Yield
| THAR Stock | 2.08 0.18 7.96% |
Tharimmune fundamentals help investors to digest information that contributes to Tharimmune's financial success or failures. It also enables traders to predict the movement of Tharimmune Stock. The fundamental analysis module provides a way to measure Tharimmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tharimmune stock.
Tharimmune | Annual Yield |
Tharimmune Company Annual Yield Analysis
Tharimmune's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Tharimmune Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Tharimmune is extremely important. It helps to project a fair market value of Tharimmune Stock properly, considering its historical fundamentals such as Annual Yield. Since Tharimmune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tharimmune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tharimmune's interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Tharimmune has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Tharimmune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tharimmune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tharimmune's managers, analysts, and investors.Environmental | Governance | Social |
Tharimmune Fundamentals
| Return On Equity | -4.55 | ||||
| Return On Asset | -1.65 | ||||
| Current Valuation | 81.67 K | ||||
| Shares Outstanding | 1.49 M | ||||
| Shares Owned By Insiders | 1.79 % | ||||
| Shares Owned By Institutions | 1.63 % | ||||
| Number Of Shares Shorted | 95.63 K | ||||
| Price To Book | 1.02 X | ||||
| EBITDA | (9.3 M) | ||||
| Net Income | (9.32 M) | ||||
| Total Debt | 1.82 M | ||||
| Book Value Per Share | 2.35 X | ||||
| Cash Flow From Operations | (7.3 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | 61.01 X | ||||
| Target Price | 4.0 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 3.36 M | ||||
| Total Asset | 10.95 M | ||||
| Retained Earnings | (24.7 M) | ||||
| Working Capital | 9.13 M | ||||
| Net Asset | 10.95 M |
About Tharimmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tharimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tharimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tharimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Tharimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tharimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tharimmune will appreciate offsetting losses from the drop in the long position's value.Moving against Tharimmune Stock
| 0.62 | HCM | HUTCHMED DRC | PairCorr |
| 0.6 | GANX | Gain Therapeutics | PairCorr |
| 0.59 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.56 | BCTXW | BriaCell Therapeutics | PairCorr |
| 0.48 | EBS | Emergent Biosolutions | PairCorr |
The ability to find closely correlated positions to Tharimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tharimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tharimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tharimmune to buy it.
The correlation of Tharimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tharimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tharimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tharimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.